PE/Cyanine7 anti-mouse CD8a Antibody

Pricing & Availability
Clone
53-6.7 (See other available formats)
Regulatory Status
RUO
Other Names
T8, Lyt2, Ly-2
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
53-6pt7_PEslashCy7
C57BL/6 splenocytes were stained with CD8 (clone 53-6.7) PE/Cyanine7 and CD3 FITC.
  • 53-6pt7_PEslashCy7
    C57BL/6 splenocytes were stained with CD8 (clone 53-6.7) PE/Cyanine7 and CD3 FITC.
Compare all formats See PE/Cyanine7 spectral data
Cat # Size Price Quantity Check Availability Save
100721 25 µg 55€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100722 100 µg 159€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE/Cyanine7 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The CD8a antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is = 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Additional Product Notes

BioLegend is in the process of converting the name PE/Cy7 to PE/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our PE/Cyanine7 products. Please contact Technical Service if you have any questions.

Application References

(PubMed link indicates BioLegend citation)
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  30. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Jarick KJ, et al. 2018. Front Immunol. 9:1468. PubMed
  2. Seo JB, et al. 2019. Nat Metab. 1:86. PubMed
  3. Yu X, et al. 2020. Nat Commun. 11:1110. PubMed
  4. Vella JL, et al. 2021. Life Sci Alliance. 4:. PubMed
  5. Calabrese DR, et al. 2020. J Clin Invest. . PubMed
  6. Wu N, et al. 2020. Cell Rep. 30:1129. PubMed
  7. Alissafi T, et al. 2018. J Clin Invest. 128:3840. PubMed
  8. Tello‐Lafoz M, et al. 2017. Sci Rep. . 10.1038/s41598-017-16370-w. PubMed
  9. Denk D, et al. 2022. Immunity. 55:2059. PubMed
  10. Schönberger K, et al. 2022. Cell Stem Cell. 29:131. PubMed
  11. Ferrere G, et al. 2021. JCI Insight. 6:. PubMed
  12. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  13. Zhang R, et al. 2021. Cell Mol Immunol. 18:1222. PubMed
  14. Lechuga-Vieco AV, et al. 2020. Sci Adv. 6:eaba5345. PubMed
  15. Chappaz S, et al. 2021. Cell Reports. 36(3):109430. PubMed
  16. Garcia-Fabiani MB, et al. 2020. Methods Enzymol. 632:369. PubMed
  17. Marco Barros R, et al. 2016. Cell. 167: 203-218. PubMed
  18. Baram T, et al. 2021. Cells. 10:. PubMed
  19. Piepke M, et al. 2021. J Neuroinflammation. 18:265. PubMed
  20. Luo R, et al. 2021. Theranostics. 11:117. PubMed
  21. Hu J, et al. 2021. Sci Adv. 7:. PubMed
  22. Mei S, et al. 2022. Front Immunol. 13:911164. PubMed
  23. Ma F, et al. 2020. Cell Death Dis. 1.172222222. PubMed
  24. Wu FTH, et al. 2019. Br J Cancer. 120:196. PubMed
  25. Chow MT et al. 2019. Immunity. 50(6):1498-1512 . PubMed
  26. Zhao J, et al. 2019. Nat Commun. 10:899. PubMed
  27. Bowers E, et al. 2018. Nat Med. 24:95. PubMed
  28. Leier A, et al. 2022. Mol Ther Nucleic Acids. 28:261. PubMed
  29. Andreas N, et al. 2021. Arthritis Res Ther. 23:222. PubMed
  30. Alotaibi F, et al. 2021. Front Immunol. 11:584937. PubMed
  31. Snyder LM, et al. 2021. PLoS Pathog. 17:e1009970. PubMed
  32. del Rio ML, et al. 2021. Transl Res. Online ahead of print.. PubMed
  33. Chen WS, et al. 2021. Cell Rep. 37:109974. PubMed
  34. Tan X, et al. 2021. Front Oncol. 11:768222. PubMed
  35. Ma C, et al. 2021. Signal Transduct Target Ther. 6:353. PubMed
  36. Saito S, et al. 2020. Nutrients. 12:. PubMed
  37. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  38. Plumlee CR, et al. 2020. Cell Host Microbe. 29(1):68-82.e5. PubMed
  39. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  40. Hung PJ, et al. 2018. Mol Cell. 71:332. PubMed
  41. Cai B, et al. 2021. Mol Cancer. 20:165. PubMed
  42. Papafragkos I, et al. 2022. Front Immunol. 13:889075. PubMed
  43. Neubert K, et al. 2014. J Immunol. 192:5830. PubMed
  44. Sakthivel P, et al. 2014. PLoS One. 9:100970. PubMed
  45. Starkl P, et al. 2020. Immunity. 53(4):793-804.e9. PubMed
  46. Peng Z, et al. 2021. STAR Protocols. 2(2):100595. PubMed
  47. Okuniewska M, et al. 2021. Cell Reports. 36(2):109368. PubMed
  48. Zhao B, et al. 2021. Cell Reports. 36(3):109401. PubMed
  49. Pan H, et al. 2020. Mol Psychiatry. . PubMed
  50. Brooks JF, et al. 2020. Cytotherapy. 22:436. PubMed
  51. Nakamura‐Ishizu A et al. 2018. Cell reports. 25(7):1772-1785 . PubMed
  52. Guo HF, et al. 2021. Commun Biol. 4:482. PubMed
  53. Perner C, et al. 2020. Immunity. 53(5):1063-1077.e7. PubMed
  54. Yi M, et al. 2021. J Hematol Oncol. 14:27. PubMed
  55. Guo Z, et al. 2016. Nat Commun. 7:10307. PubMed
  56. Shade K, et al. 2015. J Exp Med. 212:457. PubMed
  57. Liu J, et al. 2012. PLoS One. 7:e44044. PubMed
  58. He W et al. 2018. Immunity. 49(6):1175-1190 . PubMed
  59. Liu H, et al. 2020. Cancer Cell. 37(3):324-339. PubMed
  60. Marchingo JM, et al. 2020. eLife. 9:e53725.. PubMed
  61. Alsaleh G, et al. 2020. Elife. 9: . PubMed
  62. Cheng K, et al. 2021. Nat Commun. 12:2041. PubMed
  63. Yang K, et al. 2022. J Clin Invest. 132:. PubMed
  64. Zebley CC, et al. 2021. Cell Rep. 37:109796. PubMed
  65. Dane EL, et al. 2022. Nat Mater. 21:710. PubMed
  66. Guo W, et al. 2022. J Immunother Cancer. 10:. PubMed
  67. Zhao F, et al. 2022. Front Immunol. 13:873720. PubMed
  68. Wei M, et al. 2014. Protein Eng Des Sel. 27:289. PubMed
  69. Collinson-Pautz M, et al. 2016. PLoS One. 11:e0164547. PubMed
  70. Amor C, et al. 2020. Nature. 583:127. PubMed
  71. Dumas AA, et al. 2020. EMBO J. 39:e103790. PubMed
  72. Szafran BN, et al. 2021. Chemical Research in Toxicology. 34(6):1556-1571. PubMed
  73. Li J, et al. 2020. Cancer Discov. . PubMed
  74. Wei SC, et al. 2020. Cancer Discov. . PubMed
  75. Yang S, et al. 2019. Nat Commun. 10:2782. PubMed
  76. Wang GZ, et al. 2019. Nat Commun. 10:1125. PubMed
  77. Dar HY, et al. 2018. Sci Rep. 8:2503. PubMed
  78. Daniel CJ, et al. 2022. Mol Cancer Res. 20:1151. PubMed
  79. Sodji QH, et al. 2022. Cancer Res Commun. 2:725. PubMed
  80. Mehta AK, et al. 2021. Nat Cancer. 2:66. PubMed
  81. Wang Y, et al. 2021. Sci Rep. 1.429861111. PubMed
  82. Li J, et al. 2020. Cancer Immunol Res. 0.529166667. PubMed
  83. Köchl R, et al. 2020. Elife. 9:00. PubMed
  84. Sullivan B, et al. 2015. PLoS Pathog. 11:1004588. PubMed
  85. Dar HY, et al. 2018. Bone Rep. 8:46. PubMed
  86. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
  87. Yue X, et al. 2019. Nat Commun. 10:2011. PubMed
  88. Li J, et al. 2018. Immunity. 49:178. PubMed
  89. Domingo–Gonzalez R, et al. 2020. eLife. 9:e56890.. PubMed
  90. Lu Y, et al. 2021. Gastroenterology. 161:575. PubMed
  91. Taniguchi H, et al. 2022. Cell Rep. 39:110814. PubMed
  92. Progatzky F, et al. 2021. Nature. 599:125. PubMed
  93. Akazawa S, et al. 2021. Diabetologia. 64:878. PubMed
  94. Chin AL, et al. 2021. Nat Commun. 12:5138. PubMed
  95. Lehmann M, et al. 2016. J Leukoc Biol. 99: 1057 - 1064. PubMed
  96. Walter F, et al. 2020. PLoS One. 15:e0239369. PubMed
  97. Gong Y, et al. 2020. Cell Metabolism. 33(1):51-64.e9. PubMed
  98. Qi S et al. 2016. eLife. 5 pii: e14756. PubMed
  99. Pinho S, et al. 2022. Nat Cell Biol. 24:290. PubMed
  100. , et al. 2021. Eur J Immunol. 51:2708. PubMed
  101. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  102. Reese B, et al. 2020. J Immunol. 205:3218. PubMed
  103. Mulas F, et al. 2020. Cell Mol Immunol. . PubMed
  104. Wen Y, et al. 2020. Hypertension. 869:75. PubMed
  105. Zhang H, et al. 2019. Mol Cell. 76:110. PubMed
  106. Cheng Y, et al. 2019. Clin Cancer Res. 25:2621. PubMed
  107. Pietronigro E, et al. 2019. Sci Rep. 9:12055. PubMed
  108. Liang J, et al. 2020. Sci Adv. 6:eabc3646. PubMed
  109. Tan X, et al. 2021. Sci Adv. 7: . PubMed
  110. Sapra L, et al. 2021. Sci Rep. 11:1807. PubMed
  111. Alameh MG, et al. 2021. Immunity. 54:2877. PubMed
  112. Jorapur A, et al. 2022. PLoS Pathog. 18:e1010200. PubMed
  113. Yang Y, et al. 2022. Elife. 11:. PubMed
  114. Kim S, et al. 2021. Elife. 10:. PubMed
  115. Anger-Góra N, et al. 2021. Oncol Lett. 22:582. PubMed
  116. Abramowski P, et al. 2014. J Neuroimmunol. 274:111. PubMed
  117. Ariyoshi Y, et al. 2016. Gene Ther. 10.1038/gt.2016.7. PubMed
  118. Deerhake ME, et al. 2021. Immunity. 54(3):484-498.e8. PubMed
  119. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
  120. Kyburz A, et al. 2019. J Allergy Clin Immunol. 143:1496. PubMed
  121. Yu X, et al. 2019. Nat Commun. 10:574. PubMed
  122. Chatterjee S et al. 2017. Cell metabolism. 27(1):85-100 . PubMed
  123. Xiao L, et al. 2021. Clin Cancer Res. 27:4338. PubMed
  124. Ding P, et al. 2022. Bone Res. 10:42. PubMed
  125. Lang V, et al. 2021. Elife. 10:. PubMed
  126. Li H, et al. 2021. Adv Sci (Weinh). 2001596:8. PubMed
  127. Chulpanova DS, et al. 2021. Biology (Basel). 10:. PubMed
  128. Xu Q, et al. 2021. Theranostics. 11:1937. PubMed
  129. Yabas M, et al. 2016. PLoS One. 11: 0146774. PubMed
  130. Timilshina M, et al. 2017. PLoS One. 10.1371/journal.pone.0168942. PubMed
  131. Jandke A, et al. 2020. Nat Commun. 3.075694444. PubMed
  132. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  133. Kalafati L, et al. 2020. Cell. 183:771. PubMed
  134. Muri J, et al. 2020. eLife. 9:e53627.. PubMed
  135. He J, et al. 2020. Evid Based Complement Alternat Med. 2020:5637507. PubMed
  136. Yuan X, et al. 2017. Elife. 6:e29540. PubMed
  137. Nelson CE et al. 2019. Cell Rep. 28(12):3092-3104 . PubMed
  138. Hsu M, et al. 2022. Nat Immunol. 23:581. PubMed
  139. Sakamoto K, et al. 2021. Immunity. 54:2321. PubMed
  140. Zhang S, et al. 2022. Nat Commun. 13:4744. PubMed
  141. Robertson TF, et al. 2021. J Cell Biol. 220:. PubMed
  142. Niderla-Bielinska J, et al. 2021. Int J Mol Sci. :22. PubMed
  143. Chen R, et al. 2021. Cell Reports. 34(7):108751. PubMed
  144. Itoga M, et al. 2015. PLoS One. 10: e0123210. PubMed
  145. Emily A Thompson et al. 2019. Cell reports. 26(11):2859-2867 . PubMed
  146. Oliveira AC et al. 2017. eLife. 6 pii: e30883. PubMed
  147. Zhang X, et al. 2021. Nat Commun. 12:4536. PubMed
  148. Bhatt D, et al. 2021. J Exp Med. 218:. PubMed
  149. Wang D, et al. 2022. EMBO Rep. 23:e53691. PubMed
  150. Schönberger K, et al. 2022. STAR Protoc. 3:101408. PubMed
  151. Kojima H, et al. 2021. Scand J Immunol. 93:e13020. PubMed
  152. X X, et al. 2016. J Immunol . 197: 1683-1691. PubMed
  153. Gomzikova MO, et al. 2020. Pharmaceutics. 12:00. PubMed
  154. Ligon MM, et al. 2020. Mucosal Immunol. 1.172222222. PubMed
  155. Yu M, et al. 2021. Molecular Cell. 81(6):1216-1230.e9. PubMed
  156. Wedekind MF, et al. 2021. iScience. 24(7):102759. PubMed
  157. Silva DA, et al. 2019. Nature. 565:186. PubMed
  158. Lee YS, et al. 2019. Sci Adv. 5:eaaw4176. PubMed
  159. Chen Y, et al. 2022. Nat Commun. 13:4468. PubMed
  160. Bell CR, et al. 2022. Nat Commun. 13:2063. PubMed
  161. Xiao Y, et al. 2021. Cell. 184:6037. PubMed
  162. Abdelsamed HA, et al. 2020. Nat Immunol. 1.276388889. PubMed
  163. Sebina I, et al. 2016. PLoS Pathog. 12:e1005999. PubMed
  164. Baglaenko Y, et al. 2016. PLoS One. 11: 0150515. PubMed
  165. Yoshida H, et al. 2019. Cell. 176:897. PubMed
  166. Chao JL, et al. 2021. Cell Rep Med. 2:100399. PubMed
  167. Rouse MD, et al. 2020. Front Microbiol. 11:414. PubMed
  168. Lopes N, et al. 2022. Elife. 11:. PubMed
  169. Tang S, et al. 2022. Virol J. 19:32. PubMed
  170. Pantelidou C, et al. 2022. NPJ Breast Cancer. 8:102. PubMed
  171. Fitzpatrick Z, et al. 2020. Nature. 587:472. PubMed
  172. Liu Q, et al. 2021. Adv Mater. 33:e2102852. PubMed
  173. Hoechst B, et al. 2016. J Immunol. 195:1517-1523. PubMed
  174. Chakraborty P, et al. 2020. Cell Reports. 28(7):1879-1893.e7.. PubMed
  175. Ding Z, et al. 2017. Sci Rep. 10.1038/s41598-017-12488-z. PubMed
  176. Chryplewicz A, et al. 2022. Cancer Cell. 40:1111. PubMed
  177. Lau P, et al. 2022. Cell Mol Immunol. :. PubMed
  178. Xiao Z, et al. 2022. Mater Today Bio. 15:100297. PubMed
  179. Schmit T, et al. 2022. Cell Rep. 38:110456. PubMed
  180. Wang X, et al. 2022. Elife. 11:. PubMed
  181. Endo-Umeda K, et al. 2021. Sci Rep. 11:22595. PubMed
  182. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  183. Sharma R, et al. 2021. J Neuroinflammation. 72:18. PubMed
  184. Bonavita E, et al. 2020. Immunity. 1215:53. PubMed
  185. Siolas D, et al. 2021. Cell Reports. 36:109578. PubMed
  186. Sheng J, et al. 2021. eLife. 10:00. PubMed
  187. Mykkänen O, et al. 2014. PLoS One. 9:114790. PubMed
  188. Timilshina M, et al. 2020. Cell Reports. 27(10):2948-2961.e7.. PubMed
  189. Lai NY, et al. 2020. Cell. 180:33:00. PubMed
  190. Wang X, et al. 2021. Sci Transl Med. 13:. PubMed
  191. Goubet AG, et al. 2021. Cell Death Differ. 28:2276. PubMed
  192. Petty AJ, et al. 2021. JCI Insight. 6:. PubMed
  193. Goc J, et al. 2021. Cell. 184:5015. PubMed
  194. Kim SH, et al. 2020. Neoplasia. 1.3375. PubMed
  195. Reinke S, et al. 2020. Cell Reports. 30(8):2501-2511. PubMed
  196. Brenner E, et al. 2020. Nat Commun. 11:1335. PubMed
  197. Tan DQ, et al. 2019. Cell Rep. 26:2316. PubMed
  198. Yáñez A et al. 2017. Immunity. 47(5):890-902 . PubMed
  199. Chen S, et al. 2018. Nat Commun. 9:5298. PubMed
  200. Aurélien Trompette et al. 2018. Immunity. 48(5):992-1005 . PubMed
  201. Plaza-Sirvent C, et al. 2021. Front Immunol. 12:705436. PubMed
  202. Fearon AE, et al. 2021. iScience. 24:103143. PubMed
  203. Lal JC, et al. 2021. Breast Cancer Res. 23:83. PubMed
  204. Aggarwal N, et al. 2021. Cell Rep. 37:110170. PubMed
  205. Avgustinova A, et al. 2021. Cell Stem Cell. . PubMed
  206. Ye Y, et al. 2020. Genome Med. 0.557638889. PubMed
RRID
AB_312760 (BioLegend Cat. No. 100721)
AB_312761 (BioLegend Cat. No. 100722)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
UniProt
View information about CD8alpha on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD8a Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD8a 53-6.7 FC
Biotin anti-mouse CD8a 53-6.7 FC,IHC
FITC anti-mouse CD8a 53-6.7 FC
PE anti-mouse CD8a 53-6.7 FC
PE/Cyanine5 anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC-F,IP
PE/Cyanine7 anti-mouse CD8a 53-6.7 FC
APC/Cyanine7 anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 488 anti-mouse CD8a 53-6.7 FC,3D IHC
Alexa Fluor® 647 anti-mouse CD8a 53-6.7 FC,IHC-F,3D IHC,SB
Pacific Blue™ anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 700 anti-mouse CD8a 53-6.7 FC
PerCP/Cyanine5.5 anti-mouse CD8a 53-6.7 FC
PerCP anti-mouse CD8a 53-6.7 FC
Brilliant Violet 421™ anti-mouse CD8a 53-6.7 FC,IHC,SB
Brilliant Violet 570™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 650™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 605™ anti-mouse CD8a 53-6.7 FC
Ultra-LEAF™ Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC,IP,Depletion,Block
Brilliant Violet 711™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 785™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 510™ anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a (Maxpar® Ready) 53-6.7 FC,CyTOF®
Alexa Fluor® 594 anti-mouse CD8a 53-6.7 IHC-F,FC,3D IHC
PE/Dazzle™ 594 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 750 anti-mouse CD8a 53-6.7 FC
GoInVivo™ Purified anti-mouse CD8a 53-6.7 FC
TotalSeq™-A0002 anti-mouse CD8a 53-6.7 PG
Spark Blue™ 550 anti-mouse CD8a 53-6.7 FC
Spark NIR™ 685 anti-mouse CD8a 53-6.7 FC
TotalSeq™-C0002 anti-mouse CD8a 53-6.7 PG
TotalSeq™-B0002 anti-mouse CD8a 53-6.7 PG
Spark YG™ 570 anti-mouse CD8a 53-6.7 IHC-F
PE/Fire™ 640 anti-mouse CD8a 53-6.7 FC
PE/Fire™ 700 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 574 anti-mouse CD8a Antibody 53-6.7 FC
Spark Violet™ 423 anti-mouse CD8a Antibody 53-6.7 FC
Spark UV™ 387 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 515 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark Red™ 718 anti-mouse CD8a (Flexi-Fluor™) 53-6.7 FC
PE/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark PLUS UV™ 395 anti-mouse CD8a 53-6.7 FC
Go To Top Version: 2    Revision Date: 01/21/2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account